Forecast horizon — calibration-scored at resolution.
By 2028, quadruple therapy (ACEi/ARNI + BB + MRA + SGLT2i) will be the default HFrEF regimen in US registries.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray et al. · New England Journal of Medicine · 2019
· openalex W2974260792
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1242
By 2028, SGLT2 inhibitors will be prescribed for ≥70% of eligible HFrEF patients at guideline-adherent cardiology practices.
0.1253
By 2028, ARNI will remain preferred over ACEi as baseline RAS modulation in HFrEF across US and EU guidelines.
0.1917
The PARADIGM-HF trial's stated primary conclusion — Sacubitril/valsartan (ARNI) reduces CV death and HF hospitalization vs. enalapril in HFrEF. — replicates in independent cohorts.
0.1976
SGLT2 inhibitor class benefits observed in type 2 diabetes cardiovascular outcome trials will generalize to the broader HFrEF population, including patients without diabetes.
0.2180
The DAPA-HF trial's stated primary conclusion — Dapagliflozin reduces heart-failure worsening and CV death in HFrEF with or without diabetes. — replicates in independent cohorts.
0.2194
LCZ696 will demonstrate superiority over enalapril in reducing cardiovascular death or heart failure hospitalization across diverse real-world HFrEF populations, including those underrepresented in PARADIGM-HF.